Baseline data stratified according to treatment allocation.

<p>NYHA: New York Heart Association; TIA: transient ischemic attack; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker.</p

Results from cardiac imaging exams, New York Heart Association (NYHA) classification and quality of life measurements.

<p>*This row represents left ventricular ejection fraction (LVEF) by magnetic resonance imaging (MRI) or, if the latter result was not available at both baseline and follow-up, LVEF by echocardiography (E/D, N = 18). ^† p < 0.05 for difference between baseline and follow-up. CI: confidence interval; EDV: end diastolic left ventricular internal volume; ESV: end systolic left ventricular internal volume; NT-proBNP: N-terminal pro-B-type natriuretic peptide; LDL: low density lipoprotein; MLHFQ: Minnesota Living with Heart Failure Questionnaire; VAS: visual analogue scale.</p

Correlation between left ventricular ejection fraction as measured by echocardiography and as measured by magnetic resonance imaging.

<p>Data from baseline and follow-up are pooled. The Pearson correlation coefficient between results obtained by magnetic resonance imaging (MRI) and results obtained by echocardiography was 0.82 (p < 0.001).</p

Changes in markers of inflammation and extracellular matrix turnover.

<p>Changes in C-reactive protein (CRP), soluble tumor necrosis factor receptor type 1 (sTNF-R1), and procollagen type I and III N-terminal pro-peptides (PINP and PIIINP) stratified by treatment allocation. p-values for between-group differences in changes were computed by independent group t-tests. While PINP increased more in patients treated with rosuvastatin as compared to patients treated with placebo (p  =  0.03), treatment did not affect any of the other markers of inflammation or matrix remodeling. Boxes: 25–75 percentiles; whiskers: 5–95 percentiles.</p

Trial flow chart.

<p>Trial flow chart.</p

Results of blood tests.

<p>* p < 0.05 for difference between baseline and follow-up. CI: confidence interval; LDL: low density lipoprotein; HDL: high density lipoprotein; NT-proBNP: N-terminal pro-B-type natriuretic peptide; sTNF-R1: soluble tumour necrosis factor receptor 1; MCP-1: monocyte chemotactic protein-1; gp130: Soluble glycoprotein 130; MMP-9: matrix metalloproteinase-9; PINP: procollagen type I N-terminal pro-peptide; PIIINP: procollagen type III N-terminal pro-peptide.</p